Role of urokinase plasminogen activator receptor (CD87) as a prognostic marker in acute myeloid leukemia

Abstract

Expression of uPAR (CD87) may play a relevant role in the diagnosis and pathophysiology and prognostic pattern of acute myeloid leukemia. The aims of this study were to find out the prognostic significance of pretreatment detection of CD87 and study the prevalence of CD87 expression and its value as a predictor for survival in AML patients. CD87 expression has been studied on blasts in 110 newly diagnosed AML patients. Immunophenotyping and cytogenetic analysis of these cases were performed. CD87 was positive in 80 (72.7%) cases of patients. The MFI categorized the expression of CD87 into CD87(High) and CD87(Low) expression. Blast cells show that monocytic differentiation has a significantly more CD87(High) expression than CD87(Low) expression. Cytogenetic abnormalities were found in 58.7% of patients with CD87(Low) AML and 41.25% of patients with CD87(High) AML. Cases with CD87(High) expression cells were characterized by a significantly lower survival period especially when co-expressed with CD56, CD34, and/or CD64. There is a negative prognostic influence of the expression of CD87 on the surface of AML blasts, but more tests are necessary to explain the pathophysiological mechanisms behind these findings and to learn about the mechanism that influences the CD87 expression and function.

Clinical Significance of CD87 Expression in Acute Myeloblastic Leukemia.

“…6 A recent study by Atfy et al reported the highest expression rate for AML-M4, M5 and the lowest expression rate for AML-M0 subtypes. 12 Lanza et al demonstrated that CD87 expression showed a heterogenous pattern associated with the maturation level of myeloblasts and the reactivity depending on the associated cell (granulocytic or monocytic). 5 In that study, CD87 expression was found low in undifferentiated AML while a higher expression was observed in monoblastic AML.…”

Circulating Levels of Urokinase-Type Plasminogen Activator Receptor and D-Dimer in Patients With Hematological Malignancies

“…It will be necessary to continue recruiting cases of this subgroup to actually know the relation of the markers with the outcome of the pathology in our population. Atfy et al 24 reported on 110 patients with de novo acute myeloblastic leukemia (AML), and described uPAR prevalence (CD87) in blood cells of bone marrow determined according to immunophenotype in flow cytometry; CD87 was positive in 80 cases (73%), with a difference at P < .0188 and an association with poor survival. 24 Patients with lymphoma corresponded to incident (8 cases) and prevalent (27 cases), and there were no differences in D-D and uPAR between these subgroups.…”

“…Atfy et al 24 reported on 110 patients with de novo acute myeloblastic leukemia (AML), and described uPAR prevalence (CD87) in blood cells of bone marrow determined according to immunophenotype in flow cytometry; CD87 was positive in 80 cases (73%), with a difference at P < .0188 and an association with poor survival. 24 Patients with lymphoma corresponded to incident (8 cases) and prevalent (27 cases), and there were no differences in D-D and uPAR between these subgroups. Follow-up of these patients is described as the presence or not of accumulated outcome (nonresponders, relapse, and death); regarding the clinical response there was a difference in the presence of outcome, P < .001.…”

“…gov) using the keywords, lymphoma and uPAR, hematologic malignancies and uPAR, few publications were found; among the publications found we included those concerning leukemia, as briefly described. 6,7,24,26 In patients with B-cell lymphoproliferative disorders, insufficient information is reported, and further studies of patients with chronic lymphoproliferative disorders are needed to determine their relationship in this heterogeneous group of diseases. 5 In this study, we found no differences in the medians of D-D and uPAR between subgroups with and without outcome; however, there was a tendency toward differences for D-D (median, 2147 vs. 1050 ng/mL), and uPAR (median, 862 vs. 769 pg/L; Table 5), which could reach statistical significance when the sample size is increased.…”

Interrogating Tumor Metabolism and Tumor Microenvironments Using Molecular Positron Emission Tomography Imaging. Theranostic Approaches to Improve Therapeutics

“…Imaging of Urokinase-type Plasminogen Activator Receptor. The urokinase plasminogen activator (uPA) system consists of a proteinase, its receptor (urokinasetype plasminogen activator receptor, uPAR), and plasminogen activator inhibitors, including types 1 and 2 (Atfy et al, 2012;Ma and Tao, 2012). In some cancers, uPA plays a significant role in tumor progression, including angiogenesis, tumor growth, and metastasis.…”